GLIS2 and leukemia: Another pro-survival protein BCL-xL was also identified as a potential therapeutic vulnerability in erythroid and megakaryocytic lineage leukemias, including in the M07e AMKL cell line harboring CBFA2T3::GLIS2 (Kuusanmaki et al., 2023).